Browse Studies — Arctuva

Phase 1

(INCITE-ON) Phase I Study of i15.NKG2D.Zeta-NK Cell Conditioning in the Tumor Micro-environment in Combination With C7R.GD2.CAR-T for the Treatment of Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

The purpose of this study is to find the largest safe dose of i15.NKG2D.zeta-NK cells in combination with C7R.GD2.CAR-T cells, and additionally to evaluate how…

Relapsed NeuroblastomaRefractory NeuroblastomaRelapsed Osteosarcoma+1 more

Estimated

~$10 – $6,250

Baylor College of MedicineNCT07211737

Phase 1

Study of Tegavivint, a Transducin Beta-like Protein 1 (TBL1) Inhibitor, With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitab…

Osteosarcoma RecurrentOsteosarcoma in ChildrenRelapsed Osteosarcoma+1 more

Estimated

~$10 – $6,250

Emory UniversityNCT07144254

Phase 1

A Phase I Study of Allogeneic Ex Vivo Expanded Gamma Delta (γδ) T Cells in Combination With Dinutuximab, Temozolomide, Irinotecan, and Zoledronate in Children With Refractory/ Relapsed, or Progressive Neuroblastoma or Refractory/ Relapsed Osteosarcoma

The goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when de…

NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+2 more

Estimated

~$10 – $6,250

Emory UniversityNCT05400603